Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001297184-25-000029
Filing Date
2025-05-08
Accepted
2025-05-08 16:24:18
Documents
92
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q amph-20250331x10q.htm   iXBRL 10-Q 1966743
2 EX-31.1 amph-20250331xex31d1.htm EX-31.1 19062
3 EX-31.2 amph-20250331xex31d2.htm EX-31.2 18717
4 EX-32.1 amph-20250331xex32d1.htm EX-32.1 9731
5 EX-32.2 amph-20250331xex32d2.htm EX-32.2 9732
  Complete submission text file 0001297184-25-000029.txt   9584512

Data Files

Seq Description Document Type Size
6 EX-101.SCH amph-20250331.xsd EX-101.SCH 58585
7 EX-101.CAL amph-20250331_cal.xml EX-101.CAL 71410
8 EX-101.DEF amph-20250331_def.xml EX-101.DEF 270943
9 EX-101.LAB amph-20250331_lab.xml EX-101.LAB 486348
10 EX-101.PRE amph-20250331_pre.xml EX-101.PRE 427800
95 EXTRACTED XBRL INSTANCE DOCUMENT amph-20250331x10q_htm.xml XML 1787377
Mailing Address 11570 SIXTH STREET RANCHO CUCAMONGA CA 91730
Business Address 11570 SIXTH STREET RANCHO CUCAMONGA CA 91730 909-980-9484
Amphastar Pharmaceuticals, Inc. (Filer) CIK: 0001297184 (see all company filings)

EIN.: 330702205 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36509 | Film No.: 25926641
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)